Hind.Bio Science

Why is Hindustan Bio Sciences Ltd falling/rising?

As of 01-Sep, Hindustan Bio Sciences Ltd's stock price is at 7.91, down 4.81%. Despite the recent decline, the stock has shown strong long-term performance, with a year-to-date increase of 50.09% and rising investor interest.

As of 01-Sep, Hindustan Bio Sciences Ltd's stock price is currently at 7.91, reflecting a decrease of 0.4, or 4.81%. The stock has been experiencing a consecutive decline, having fallen for the last two days, resulting in a total drop of 9.18% during this period. This recent performance indicates that the stock is underperforming compared to its sector by 4.21%.<BR><BR>Despite the current decline, the stock has shown strong performance over longer periods. For instance, it has increased by 9.25% over the past week and 9.86% over the past month, significantly outperforming the Sensex, which has seen declines of 0.92% and 1.47%, respectively. Year-to-date, the stock has risen by an impressive 50.09%, while the Sensex has decreased by 9.71%. Additionally, over the last three years, Hindustan Bio Sciences Ltd has outperformed the benchmark with a return of 38.77% compared to the Sensex's 17.67%.<BR><BR>The stock is currently trading above its moving averages across various time frames, indicating a generally positive trend. Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 98.3% against the five-day average, suggesting growing interest despite the recent price drop.<BR><BR>In summary, while Hindustan Bio Sciences Ltd is currently experiencing a decline in stock price, its overall performance remains strong over longer periods, and increased investor participation may indicate potential for recovery.

Who are in the management team of Hind.Bio Science?

The management team of Hind.Bio Science includes J.V.R. Mohan Raju (Chairman & Managing Director), B R Rao (Independent Director), J Uma (Director), K Rama Chandra Raju (Independent Director), and M Satyanarayana Raju (Independent Director).

The management team of Hind.Bio Science includes the following individuals:<BR><BR>1. J.V.R. Mohan Raju - Chairman & Managing Director<BR>2. B R Rao - Independent Director<BR>3. J Uma - Director<BR>4. K Rama Chandra Raju - Independent Director<BR>5. M Satyanarayana Raju - Independent Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

What does Hind.Bio Science do?

Hindustan Bio Sciences Ltd manufactures and sells pharmaceutical products and operates in the Software Products industry as a Micro Cap company. It was incorporated in 1991, with a current market cap of INR 8 Cr and a P/E ratio of 61.00.

Overview:<BR>Hindustan Bio Sciences Ltd is engaged in the manufacturing and sale of pharmaceutical products and operates within the Software Products industry, categorized as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated as a Public Limited Company on December 16, 1991, and was formerly known as Hindustan Softel Ltd. It commenced operations in 1992 and the latest quarterly results reported are for June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>Market-cap value: INR 8 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 61.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 2.22<BR>Return on Equity: 14.00%<BR>Price-to-Book: 8.95<BR><BR>Contact Details:<BR>Address: H No 8-2-269/S PlotNo 31 RdNo2, Sagar Co-Op Hous Banjara Hills Hyderabad Telangana : 500034<BR>Tel: 91-40-23555161/23555181<BR>Email: pharma.hindustanbio@gmail.com<BR>Website: http://www.hindustanbiosciences.in

Who are the peers of the Hind.Bio Science?

Hind.Bio Science's peers include Indo-City Info., Cont. Chemicals, Hit Kit Global, and others. Hit Kit Global has the highest 1-year return at 99.17%, while Hind.Bio Science's return is -1.19%.

Peers: The peers of Hind.Bio Science are Indo-City Info., Cont. Chemicals, Hit Kit Global, Svam Software, First Fintec, Nihar Info Glob., Omni Ax's, Pagaria Energy, and T. Spiritual.<BR><BR>Quality Snapshot: Below Average management risk is observed at Indo-City Info., Hit Kit Global, Svam Software, Hind.Bio Science, First Fintec, Nihar Info Glob., and the rest. Average growth is found at Nihar Info Glob., while Below Average growth is noted for Indo-City Info., Hit Kit Global, Svam Software, Hind.Bio Science, First Fintec, and the rest. Below Average capital structure is seen in Indo-City Info., Hit Kit Global, Svam Software, Hind.Bio Science, First Fintec, Nihar Info Glob., and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Hit Kit Global at 99.17%, while the lowest is Cont. Chemicals at -19.74%. Hind.Bio Science's 1-year return is -1.19%, which is better than Cont. Chemicals but worse than Hit Kit Global. Additionally, the six-month return is negative for Cont. Chemicals, Svam Software, and Pagaria Energy.

How big is Hind.Bio Science?

As of 31st August, Hindustan Bio Sciences Ltd has a market capitalization of 8.00 Cr, with recent net sales of 0.38 Cr and a net loss of 0.21 Cr. Shareholder's funds are 0.90 Cr, and total assets are valued at 3.41 Cr as of March 2025.

As of 31st August, Hindustan Bio Sciences Ltd has a market capitalization of 8.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.38 Cr. However, it experienced a loss of 0.21 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 0.90 Cr and Total Assets were valued at 3.41 Cr.

Which are the latest news on Hind.Bio Science?

When is the next results date for Hindustan Bio Sciences Ltd?

The next results date for Hindustan Bio Sciences Ltd is July 31, 2026.

The next results date for Hindustan Bio Sciences Ltd is scheduled for July 31, 2026.

Are Hindustan Bio Sciences Ltd latest results good or bad?

Hindustan Bio Sciences Ltd's latest results are concerning, showing a net loss of ₹0.12 crores and zero net sales in Q4 FY26, indicating significant operational challenges and revenue volatility. The company's return on equity has also decreased, and its stock has underperformed compared to the market.

The latest results for Hindustan Bio Sciences Ltd are concerning. In the fourth quarter of FY26, the company reported a net loss of ₹0.12 crores, a significant decline from a profit of ₹0.08 crores in the previous quarter. Additionally, net sales plummeted to zero, marking a 100% decline quarter-on-quarter. This pattern of alternating between quarters with zero revenue raises serious questions about the company's operational viability.<BR><BR>The company's return on equity has also decreased, with the latest figure at 8.60%, down from 14.00%. Over the past year, the stock has underperformed, declining by 17.23%, compared to an 8.82% drop in the Sensex.<BR><BR>Overall, the financial performance indicates a troubling trend of revenue volatility and operational challenges, suggesting that the company's current situation is quite poor. The lack of consistent sales and the absence of institutional investor confidence further highlight the difficulties Hindustan Bio Sciences is facing.

Should I buy, sell or hold Hindustan Bio Sciences Ltd?

Is Hind.Bio Science overvalued or undervalued?

As of November 3, 2025, Hind.Bio Science is considered overvalued with a PE ratio of 54.70, significantly higher than its peers, and has underperformed the Sensex year-to-date, indicating a risky investment.

As of 3 November 2025, the valuation grade for Hind.Bio Science has moved from very expensive to risky. The company is currently considered overvalued. Key ratios include a PE ratio of 54.70, an EV to EBITDA of -10.08, and a PEG ratio of 0.82. <BR><BR>In comparison to its peers, Hind.Bio Science's PE ratio is significantly higher than Sun Pharma's 35.62 and Cipla's 22.44, indicating a premium valuation despite its negative earnings multiples. Additionally, while the stock has shown a strong return of 13.7% over the past week, it has underperformed the Sensex year-to-date, with a decline of 26.84%. Overall, these factors suggest that Hind.Bio Science is overvalued relative to its peers and financial metrics.

How has been the historical performance of Hind.Bio Science?

Hind.Bio Science has experienced fluctuating financial performance, with net sales declining from 3.56 Cr in Mar'19 to 0.81 Cr in Mar'25, though profitability metrics show signs of recovery, particularly with an operating profit margin improving to 12.35% in Mar'25. Total liabilities and assets have also decreased during this period, while cash flow from operations has remained stagnant.

Answer:<BR>The historical performance of Hind.Bio Science shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Hind.Bio Science's net sales have seen a decline from 3.56 Cr in Mar'19 to 0.81 Cr in Mar'25, with a peak of 1.94 Cr in Mar'20 and a slight recovery to 1.03 Cr in Mar'24 before falling again. Total operating income followed a similar trajectory, peaking at 3.56 Cr in Mar'19 and dropping to 0.81 Cr in Mar'25. The company has consistently reported no raw material costs, while the purchase of finished goods decreased from 2.92 Cr in Mar'19 to 0.49 Cr in Mar'25. Operating profit margins have fluctuated significantly, with a negative margin of -127.27% in Mar'22 improving to 12.35% in Mar'25. Profit after tax also showed volatility, moving from 0.11 Cr in Mar'19 to a loss of -0.94 Cr in Mar'21, before recovering to 0.10 Cr in Mar'25. The total liabilities have decreased from 5.55 Cr in Mar'20 to 3.41 Cr in Mar'25, while total assets have also declined from 5.55 Cr to 3.41 Cr in the same period. Cash flow from operating activities has remained stagnant, with no cash inflow or outflow recorded in the last few years. Overall, Hind.Bio Science has experienced significant fluctuations in its financial performance, with recent signs of recovery in profitability metrics.

What is the technical trend for Hind.Bio Science?

As of June 2, 2025, Hind.Bio Science shows a mildly bearish trend overall, with mixed signals from indicators suggesting some weekly strength but monthly weakness.

As of 2 June 2025, the technical trend for Hind.Bio Science has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD shows a mildly bullish signal, contrasting with the monthly MACD which is mildly bearish. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, suggesting some upward pressure. However, the KST indicates a mildly bullish trend weekly but is mildly bearish monthly. Overall, the mixed signals from the indicators suggest a mildly bearish stance with some strength in the weekly timeframe but overall weakness in the monthly perspective.

Who are the top shareholders of the Hind.Bio Science?

The top shareholder of Hind.Bio Science is promoter Venkata Rama Mohan Raju Jampana with 9.39%, followed by public shareholder Satyasai Kolli at 2.59%. Individual investors hold a substantial 84.02% of the shares, with no pledged promoter holdings or mutual fund/foreign institutional investor holdings.

The top shareholders of Hind.Bio Science include Venkata Rama Mohan Raju Jampana, who is the promoter with the highest holding at 9.39%. The highest public shareholder is Satyasai Kolli, holding 2.59%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 84.02% of the shares. There are no pledged promoter holdings, and the company does not have any mutual fund or foreign institutional investor (FII) holdings.

Has Hind.Bio Science declared dividend?

No Dividend History Available